Tags : SK Biopharmaceuticals


Arvelle Therapeutics Licenses Exclusive Development & Commercialization Rights for Cenobamate

Shots: SK Biopharmaceuticals to receive $100M upfront, $430M milestones, and royalties on sales of product. Arvelle to get exclusive rights to develop and commercialize SK’s Cenobamate in EU SK also has an option to make equity investment in Arvelle and will retain WW commercialization rights for Cenobamate (Ex-EU). Arvelle plans to file Cenobamate’s MAA to […]Read More